dc.creator | Belvis Jiménez, María Inmaculada | es |
dc.creator | Pino Bellido, Pilar del | es |
dc.creator | Castro Laria, Luisa | es |
dc.creator | Maldonado Pérez, María Belén | es |
dc.creator | Sáez Díaz, Antonia | es |
dc.creator | Caunedo Álvarez, Ángel | es |
dc.creator | Argüelles Arias, Federico | es |
dc.date.accessioned | 2024-05-13T14:16:01Z | |
dc.date.available | 2024-05-13T14:16:01Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Belvis Jiménez, M.I., Pino Bellido, P.d., Castro Laria, L., Maldonado Pérez, M.B., Sáez Díaz, A., Caunedo Álvarez, Á. y Argüelles Arias, F. (2020). Vedolizumab response in inflammatory bowel disease. Two years of follow-up. Revista Española de Enfermedades Digestivas, 112 (7), 555-558. https://doi.org/10.17235/reed.2020.7130/2020. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/158235 | |
dc.description.abstract | Background: vedolizumab is an α4β7 integrin antagonist.
The aim of this study was to evaluate the clinical response
and remission rates with vedolizumab.
Methods: this was a retrospective study of inflammatory
bowel disease (IBD) patients who received vedolizumab
between 2016 and 2019. Response and remission rates
were analyzed at three, six, 12, 18 and 24 months after
induction.
Results: fifty-five patients were included. Clinical remis
sion rates in CD and UC at three, six, 12, 18 and 24 months
were 19.35 %, 26.67 %, 30.43 %, 30 %, 38.89 % and 29.17 %,
26.09 %, 19.05 %, 26.67 % and 20 %, respectively.
Conclusions: vedolizumab is effective for induction and
maintenance of clinical remission, both in Crohn’s disease
and ulcerative colitis. | es |
dc.format | application/pdf | es |
dc.format.extent | 4 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 112 (7), 555-558. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Vedolizumab | es |
dc.subject | Response | es |
dc.subject | Remission | es |
dc.title | Vedolizumab response in inflammatory bowel disease. Two years of follow-up | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/vedolizumab-response-in-inflammatory-bowel-disease-two-years-of-follow-up5058 | es |
dc.identifier.doi | 10.17235/reed.2020.7130/2020 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 112 | es |
dc.publication.issue | 7 | es |
dc.publication.initialPage | 555 | es |
dc.publication.endPage | 558 | es |